Ricki Lewis | Apr 11, 1999 | 5 min read
While prominent scientists plead with legislators to reconsider their conservative stance on funding human embryonic stem (ES) cell research, a six-year-old company in Baltimore is quietly making the matter moot. In a just-released tour-de-force research report, it is no longer quite so quiet.1 Researchers at Osiris Therapeutics and the Johns Hopkins University School of Medicine coaxed human mesenchymal stem cells (hMSCs) from adults' bone marrow to develop into cartilage, fat, and bone cells